Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
DIVIS LABORATORIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-23 |
ADCOCK INGRAM Jun-14 |
DIVIS LABORATORIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,641 | 320 | - | |
Low | Rs | 2,730 | 231 | - | |
Sales per share (Unadj.) | Rs | 292.6 | 95.1 | - | |
Earnings per share (Unadj.) | Rs | 68.7 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 81.6 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 30.00 | 0 | - | |
Avg Dividend yield | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 480.9 | 74.6 | - | |
Shares outstanding (eoy) | m | 265.47 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 12.6 | 2.9 | 435.3% | |
Avg P/E ratio | x | 53.7 | -11.5 | -467.3% | |
P/CF ratio (eoy) | x | 45.2 | -13.9 | -325.9% | |
Price / Book Value ratio | x | 7.7 | 3.7 | 207.9% | |
Dividend payout | % | 43.7 | 0 | - | |
Avg Mkt Cap | Rs m | 978,378 | 46,446 | 2,106.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 9,750 | 2,915 | 334.5% | |
Avg. sales/employee | Rs Th | 0 | 3,739.2 | - | |
Avg. wages/employee | Rs Th | 0 | 679.0 | - | |
Avg. net profit/employee | Rs Th | 0 | -942.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 77,675 | 16,052 | 483.9% | |
Other income | Rs m | 3,447 | 112 | 3,066.1% | |
Total revenues | Rs m | 81,122 | 16,165 | 501.8% | |
Gross profit | Rs m | 23,691 | -2,782 | -851.7% | |
Depreciation | Rs m | 3,432 | 693 | 495.3% | |
Interest | Rs m | 20 | 435 | 4.5% | |
Profit before tax | Rs m | 23,686 | -3,797 | -623.8% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,453 | 237 | 2,298.1% | |
Profit after tax | Rs m | 18,234 | -4,045 | -450.8% | |
Gross profit margin | % | 30.5 | -17.3 | -176.0% | |
Effective tax rate | % | 23.0 | -6.2 | -368.4% | |
Net profit margin | % | 23.5 | -25.2 | -93.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 97,437 | 11,757 | 828.8% | |
Current liabilities | Rs m | 15,331 | 6,615 | 231.8% | |
Net working cap to sales | % | 105.7 | 32.0 | 330.0% | |
Current ratio | x | 6.4 | 1.8 | 357.6% | |
Inventory Days | Days | 8 | 111 | 7.6% | |
Debtors Days | Days | 842 | 124 | 679.6% | |
Net fixed assets | Rs m | 51,128 | 6,853 | 746.1% | |
Share capital | Rs m | 531 | 75 | 712.3% | |
Net worth | Rs m | 127,671 | 12,599 | 1,013.3% | |
Long term debt | Rs m | 0 | 4,428 | 0.0% | |
Total assets | Rs m | 148,565 | 23,801 | 624.2% | |
Interest coverage | x | 1,209.5 | -7.7 | -15,642.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.7 | 77.5% | |
Return on assets | % | 12.3 | -15.2 | -81.0% | |
Return on equity | % | 14.3 | -32.1 | -44.5% | |
Return on capital | % | 18.6 | -19.8 | -93.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 24,597 | 1,370 | 1,795.2% | |
From Investments | Rs m | -27,076 | -421 | 6,435.8% | |
From Financial Activity | Rs m | -7,972 | 4,018 | -198.4% | |
Net Cashflow | Rs m | -10,451 | 4,968 | -210.4% |
Compare DIVIS LABORATORIES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare DIVIS LABORATORIES With: ZIM LABORATORIES ZENOTECH LABS VEERHEALTH CARE IOL CHEMICALS & PHARM. AARTI PHARMALABS
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.